Bakkenolide B (intraperitoneal injection; 1 mg/ml; 1 h before ovalbumin nebulization on days 28, 29, and 30) strongly inhibits the accumulation of eosinophils, macrophages, and lymphocytes to bronchoalveolar lavage fluid (BALF) in ovalbumin-induced asthma mice[1].
| Animal Model: | Ovalbumin-induced asthma mice[1] |
| Dosage: | 1 mg/ml |
| Administration: | Intraperitoneal injection; 1 h before ovalbumin nebulization on days 28, 29, and 30 |
| Result: | Exhibited anti-allergic effects in mice. |
